Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 56 (-6.7%)ASK Investment₹ 925 (0%)Axles India₹ 525 (0%)CIAL ₹ 444 (1.4%)CSK ₹ 262 (-2.2%)ESDS Software₹ 465 (3.8%)Garuda Aerospace₹ 478 (-1.4%)India Carbon₹ 895 (0%)Indian Potash₹ 2850 (0%)Inox Clean₹ 725 (0%)Insolare Energy₹ 185 (0%)Lava ₹ 52 (0%)Matrix Gas₹ 15 (-6.2%)Motilal Oswal₹ 12.5 (-3.5%)MSEI ₹ 6.5 (4%)NCDEX ₹ 374 (-6%)NeRL ₹ 56 (-3.4%)NSE ₹ 2025 (3.1%)OYO ₹ 24 (0%)OYO Assets₹ 9.95 (-17.1%)Pharmeasy ₹ 6.25 (0%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 58 (-6.5%)RRP S4E₹ 158 (-6%)SBI Mutual₹ 775 (0%)Taparia Tools₹ 6050 (0%)Ticker Ltd₹ 32 (0%)Zepto ₹ 42 (-14.3%)

15 Days Price Change

Emcure Pharma IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 1981 Industry: Pharmaceuticals & Drugs Listed Page

Profile
Issue Size --
Profile
Price Range 960  to  1008 per share
Profile
Min Investment ₹1008
Profile
Lot Size 1
Profile
Face Value ₹10
Profile
Draft Prospectus --
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

Emcure Pharmaceuticals, founded in 1981 in Pune, India, has grown into a prominent player in the global pharmaceutical industry. Specializing in a broad spectrum of therapeutic segments including cardiovascular, diabetes, oncology, nephrology, and more, Emcure manufactures and markets pharmaceutical products worldwide. The company operates state-of-the-art manufacturing facilities in India, adhering to rigorous international quality standards and holding certifications from regulatory bodies such as the US FDA and WHO. Emcure's global footprint extends to over 70 countries, exporting its products across Europe, the United States, Africa, Asia-Pacific, and other regions. With a strong emphasis on research and development, Emcure invests in innovative generic and specialty pharmaceuticals. Additionally, the company actively engages in corporate social responsibility initiatives, supporting healthcare, education, and community development projects. Emcure Pharmaceuticals continues to expand its presence and influence in the global healthcare market through its commitment to quality, innovation, and societal impact. Read More

Basic Info

Face Value 10 per share

Price 960  to  1008 per share

P/E (x) 27.7

Sales( Cr.) 7896

PAT( Cr.) 707

EPS 36.4

Draft Prospectus --

Exchange BSE-NSE

Promoter

Company Promoters

Satish Mehta Sunil Mehta

Pre Issue Share Holding 100%

Post Issue Share Holding 69.07%

Listing Details:

Listing Price: 1325.05

Listing Gain: 23.93%

Current Price: 1704.9

Gain On Issue: 1704.9 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date Jul 03, 2024
Closing Date Jul 05, 2024
Allotment Jul 08, 2024
Refund Jul 09, 2024
Delivery of Shares Jul 09, 2024
Listing Date Jul 10, 2024

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 14 14,112
Retail (Max) 14 196 197,568
S-HNI (Min) 15 210 211,680
S-HNI (Max) 70 980 987,840
B-HNI (Min) 71 994 1,001,952

Objective of the Issue

1. Repayment and/ or prepayment of all or a portion of certain outstanding borrowings availed by the company. 2. General corporate purposes

Issue

Category Nos Bid Bid (x)
QIB 9682673 1851714385 191.2x
NII 2904802 143264835 49.3x
Retail 6777871 49885131 7.4x
EMP 0 0 0x
Total 19365346 1314326033 67.9x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Emcure Pharma Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 3777 4365 4188 4228 4717 5049 6056 5855 5986 6658 7896
Other Income 35 28 21 46 95 82 35 63 46 57 73
Total Income 3812 4393 4209 4274 4812 5131 6092 5919 6032 6715 7969
Total Expenditure 2908 3229 3336 3461 3968 4345 4824 4525 4805 5429 6427
Operating Profit 903 1164 873 813 844 786 1267 1393 1227 1287 1542
Interest 102 119 174 176 223 257 198 176 214 237 176
Depreciation 188 168 217 228 267 321 323 245 260 312 384
Exceptional Income / Expenses -244 -107 -186 -119 -23 -103 -89 0 -6 -10 -10
Profit Before Tax 370 770 296 290 331 105 657 973 747 727 971
Provision for Tax 109 201 44 116 121 5 239 270 185 200 264
Profit After Tax 261 569 251 174 209 101 419 703 562 528 707
Adjustments -5 -11 -11 1 -14 -17 -26 -40 -30 -29 -26
Profit After Adjustments 256 558 240 175 195 84 392 662 532 498 681
Adjusted Earnings Per Share 14.2 30.9 13.3 9.7 10.8 4.6 21.7 36.6 29.4 27.5 36

Emcure Pharma Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 967 1393 1582 1701 1835 1912 2273 1988 2501 2952 4446
Minority's Interest 47 61 67 54 65 72 95 127 149 169 195
Borrowings 394 928 969 806 688 553 704 717 744 767 190
Other Non-Current Liabilities 140 129 157 192 309 346 179 151 160 611 622
Total Current Liabilities 1408 1731 1817 2336 2543 2920 3408 2965 3019 3210 2668
Total Liabilities 2957 4241 4592 5089 5440 5803 6659 5947 6573 7709 8122
Fixed Assets 1129 1853 1941 2049 2247 2382 2412 2044 2147 3125 3197
Other Non-Current Assets 272 278 646 704 741 718 529 479 591 325 369
Total Current Assets 1555 2110 2005 2335 2453 2703 3717 3424 3836 4254 4556
Total Assets 2957 4241 4592 5089 5440 5803 6659 5947 6573 7709 8122

Emcure Pharma Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 344 -129 -66 71 59 -641 -609 -350 -308 -175 44
Cash Flow from Operating Activities 523 436 460 482 444 500 704 768 747 1097 852
Cash Flow from Investing Activities -431 -689 -616 -426 -409 -164 -252 -789 -468 -713 -94
Cash Flow from Financing Activities -250 303 293 -69 -735 -301 -189 -152 -145 -164 -814
Net Cash Inflow / Outflow -158 51 137 -13 -699 36 264 -172 134 221 -56
Closing Cash & Cash Equivalent 204 -66 71 59 -641 -609 -350 -308 -175 44 -14

Emcure Pharma Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 14.17 30.87 13.26 9.68 10.79 4.62 21.68 36.62 29.42 27.5 35.96
CEPS(Rs) 24.82 40.76 25.9 22.24 26.34 23.3 41.02 52.39 45.45 46.37 57.61
DPS(Rs) 3.75 10 3 3.5 3.5 2.5 1 3 2 3 3
Book NAV/Share(Rs) 53 76.02 86.22 93.15 100.63 104.23 125.04 109.02 137.48 162.17 234.02
Core EBITDA Margin(%) 22.73 25.72 20.04 18.1 15.33 13.49 19.71 22.24 19.37 18.12 18.31
EBIT Margin(%) 12.35 20.14 11.05 11 11.33 6.94 13.69 19.21 15.76 14.21 14.3
Pre Tax Margin(%) 9.69 17.43 6.95 6.86 6.77 2.02 10.52 16.27 12.25 10.72 12.11
PAT Margin (%) 6.83 12.88 5.91 4.11 4.28 1.93 6.7 11.75 9.21 7.77 8.82
Cash Profit Margin (%) 11.75 16.69 11.02 9.49 9.75 8.08 11.87 15.84 13.48 12.38 13.61
ROA(%) 12 15.81 5.69 3.6 3.97 1.79 6.72 11.15 8.97 7.39 8.94
ROE(%) 37.42 48.78 17.13 10.74 11.94 5.43 20.19 33.19 25.21 19.45 19.19
ROCE(%) 32.4 36.29 14.82 13.17 14.46 9 19.75 26.56 21.97 19.87 22.49
Receivable days 40.91 56.18 59.85 65.16 68.83 74.07 76.52 84.97 88.49 94.32 87.83
Inventory Days 39.7 63.55 81.91 82.86 76.82 80.5 78.47 90.46 84.77 78.21 78.64
Payable days 96.42 135.58 141.72 151.6 144.81 137.31 132.95 188.82 194.85 193.72 174.97
PER(x) 0 0 0 0 0 0 0 0 0 0 29.84
Price/Book(x) 0 0 0 0 0 0 0 0 0 0 4.58
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0.28
EV/Net Sales(x) 0.22 0.33 0.41 0.45 0.47 0.43 0.32 0.33 0.32 0.3 2.65
EV/Core EBITDA(x) 0.91 1.23 1.99 2.34 2.61 2.78 1.55 1.4 1.55 1.57 13.55
Net Sales Growth(%) 179.81 15.57 -4.04 0.94 11.58 7.02 19.96 -3.32 2.23 11.23 18.59
EBIT Growth(%) 175.24 88.47 -47.19 -0.75 18.68 -34.58 136.36 34.26 -16.34 0.37 18.95
PAT Growth(%) 201.82 117.98 -55.85 -30.67 20.09 -51.91 316.06 67.84 -20.03 -6.1 34.1
EPS Growth(%) 142.24 117.81 -57.04 -27 11.41 -57.14 369.03 68.87 -19.66 -6.52 30.75
Debt/Equity(x) 1.03 1.14 1.16 1.18 1.17 1.15 1.02 1.05 0.88 0.71 0.16
Current Ratio(x) 1.1 1.22 1.1 1 0.96 0.93 1.09 1.15 1.27 1.33 1.71
Quick Ratio(x) 0.66 0.69 0.56 0.6 0.52 0.52 0.65 0.67 0.81 0.85 0.98
Interest Cover(x) 4.64 7.45 2.7 2.65 2.48 1.41 4.32 6.53 4.5 4.07 6.53
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0 0 0 0.04

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 19% 10% 9% 8%
Operating Profit CAGR 20% 3% 14% 5%
PAT CAGR 34% 0% 48% 10%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 60% NA% NA% NA%
ROE Average 19% 21% 23% 23%
ROCE Average 22% 21% 22% 21%

Company Contact Information

Emcure Pharmaceuticals Ltd.

Plot No. P-1 & P-2 I T - B T Park, Phase- I I M I D C, Hinjawadi

IPO Lead Manager(s)

Emcure Pharmaceuticals Ltd.

Axis Capital Ltd.

Jefferies India Pvt Ltd.

JP Morgan India Pvt Ltd

Kotak Mahindra Capital Co Ltd

Registrar Info

Emcure Pharmaceuticals Ltd.

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Please Login!

Click to Login
OR
Get free Account

Error!